Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201

Microtia Clinical Trial

— AUR-201  

Official title:

Long-Term Follow-Up Study of Unilateral Microtia Patients Who Participated in Study AUR 201 05 and Had the AUR-201 Implant in Place at Final Visit (24 Weeks After the First Implantation Surgery)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06078566
• Other study ID #: AUR-201-06
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 26, 2024
• Est. completion date: June 2026

Study information

• Verified date: February 2024
• Source: Auregen Biotherapeutics, SA
• Contact: Michelle Nelken
• Phone: 6177554149
• Email: mnelken[@]auregen.bio
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Long-term follow-up of unilateral microtia patients implanted with AUR-201.

Description:

Long-term follow-up study of unilateral microtia patients who participated in Study AUR-201-05 and had the AUR-201 implant in place at the final visit (24 weeks post-implantation).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: June 2026
• Est. primary completion date: June 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 29 Years

Eligibility

Inclusion Criteria:

1. Participated in Study AUR-201-05 and had the AUR-201 implant (auricle* or auricle and wedge) in place at the Final Study Visit of Study AUR-201-05 (24 weeks after the first implantation surgery). *If the Principal Investigator (PI) opted not to implant the wedge component beneath the auricle component and the subject has only the auricle in place at the Final Study Visit of Study AUR-201-05, the subject will be considered eligible under this inclusion criterion;

2. Subject or guardian signed the informed consent form (ICF).

Exclusion Criteria:

1. Any condition which, in the opinion of the PI, places the subject at unacceptable risk if he/she were to participate in the study.

Related Conditions & MeSH terms

• Microtia

Intervention

Combination Product:
• AUR-201
Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.

Locations

Country	Name	City	State
United States	Romo Plastic Surgery	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Auregen Biotherapeutics, SA

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Appearance/Long-Term Durability of the AUR-201 Implant	- The primary efficacy endpoint for the assessment of long-term durability is based on the improvement in overall appearance at 48 and 96 weeks post-implantation compared to pre-implantation baseline as determined by review and rating of photographs on a 5-point Likert scale by a panel of blinded independent experts.	72 weeks. The study starts at 24 weeks post implantation and ends at 96 weeks post implantation for a total of 72 weeks for this study.
Primary	Incidence of Long Term Treatment-Emergent Adverse Events	The primary safety endpoint for the assessment of long-term safety and tolerability is based on the incidence of treatment-emergent adverse events that initiate or worsen after the Final Study Visit of Study AUR-201-05 (24 weeks post-implantation) through the Final Study Visit of this LTFU study (96 weeks post-implantation). Any untoward medical occurrence that initiates or worsens after the Final Study Visit of Study AUR-201-05 through the Final Study Visit of this study (Study AUR-201-06), whether or not considered related to AUR-201 (including the associated procedures, i.e., biopsy, implantation, and explantation), will be included as part of this end.; The severity of AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.	72 weeks. The study starts at 24 weeks post implantation and ends at 96 weeks post implantation for a total of 72 weeks for this study